Teleflex Incorporated (TFX) Earnings Call Transcript & Summary

July 30, 2020

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 80 min

Earnings Call Speaker Segments

Jake Elguicze

executive
#1

Thanks, and welcome, everyone, to the Teleflex Incorporated Second Quarter 2020 Earnings Conference Call on this good morning. You can find the press release and the slides that go with this call on our website at www.teleflex.com. Just a reminder that this call is being webcast on our site, and a replay can be accessed by calling (855) 859 to 2056, or if you're calling internationally, (404) 537 to 3406, with passcode 1778009. On the line with us today are Liam Kelly, our Chairman, President and Chief Executive Officer, along with Thomas Powell, Executive Vice President and Chief Financial Officer. Liam and Tom are going to give prepared remarks, and after that we'll open things up for Q&A. Before we get started, I want to remind everyone that certain matters we'll discuss on this conference call will include forward-looking statements about future events, as described in our slides; we'd like to caution you that these statements are indeed forward-looking in nature and are subject to risks and uncertainties, and actual events or results could differ materially. The factors that might cause actual results or events to differ materially include, but are not limited to, those referenced in our press release today and in our filings with the SEC, including our Form 10-K, which you can access on our website. Also, during this conference call, you'll hear management reference what the estimated positive or negative impacts were as a result of COVID-19 during the second quarter of 2020. You'll also hear management make statements about intra-quarter business performance during the month of July. Management is offering this commentary to give the investment community additional insights concerning trends, and these disclosures may not occur in subsequent quarters. With that said, I'd like to now turn the call over to Liam.

Liam Kelly

executive
#2

Appreciate that introduction, Jake, and hello everyone — great to have this chance to talk with you this morning. Ahead of walking through how we did this quarter, I want to extend my sympathy to everybody whose life has been touched by the coronavirus, and to express genuine gratitude toward the health care workers who face danger daily in the fight against COVID-19. I'd also like to pause and acknowledge the Teleflex team members worldwide. The last several months have been anything but ordinary. Our team members keep amazing me, finding remarkable ways to rise to the occasion so that hospitals, clinicians, and patients who depend on our products can get them when it matters most. I appreciate that; let's move into what happened in Q2. Given how the COVID-19 pandemic intensified worldwide, we feel very good about how we performed in the second quarter. It came in well above what we had anticipated internally, and it showed better month-over-month revenue patterns for those product lines hit hardest when non-emergent procedures got pushed back — especially Interventional Urology, Interventional Access, and Surgical. In the second quarter, we brought in $567 million in revenue, representing a 12% drop from the same period a year earlier when measured in constant currency. This decrease stems from COVID-19's adverse effects, which we calculate had a net negative impact of roughly $130 million, or about 20%. Had we adjusted to remove that COVID-related drag, we figure our core operations would have expanded by around 8% in constant currency terms—essentially landing at the upper portion of the 2020 full-year constant currency revenue growth range we had originally forecast. Turning to per-share profits, much like with revenue, our adjusted EPS for the quarter came in at $1.93, which likewise came in well above what we had anticipated internally. The improvement in monthly procedures that occurred as the quarter progressed is captured here, along with disciplined control of operating expenses. Also, near the close of Q2, we kicked off a plan to shrink our workforce, which positions us to take advantage of initiatives aimed at generating additional profitability over the long term; this most recent action centers mainly on consolidating selected sales and marketing roles in EMEA, plus certain manufacturing activities inside our OEM segment. Now, shifting to a closer look at what we delivered in quarter two. Quarter 2 revenue, as I noted earlier, was down 12% in constant currency terms, and on an as-reported basis the decline came to 13.1%. COVID-19 was the main reason revenue fell; we figure it cost us roughly $144 million in damage spread across a number of product categories worldwide. Partly making up for that was about $14 million in extra sales from vascular access and our other categories, where demand ran hotter than we'd anticipated because of the pandemic. Turning to margins, adjusted gross margin landed at 53.9%, while adjusted operating margin reached 21.8%. Against the prior-year period, gross margin lost 380 basis points and operating margin lost 340 basis points, as weaker sales volumes and a revenue mix that COVID made unfavorable created major drags. Partly offsetting those headwinds were our cost containment actions, as we keep trimming expenses wherever we judge it makes sense given today's conditions, while still investing enough to support our longer-term growth ambitions. Adjusted EPS came to $1.93, a 27.4% decrease versus a year ago, yet it was comfortably above what we had expected internally, because the business began recovering over the course of the quarter. And although declines in revenue and profitability compared with a year earlier are never something I enjoy seeing, I feel quite good about how we performed financially overall, since it shows how resilient the diversified global product portfolio is that we've assembled over the last few years. Now, I think it would be useful to give some context on how we observed COVID-19 affecting our second quarter results. In Q2, we estimate COVID-19 acted as a headwind to revenue in Interventional Urology, Surgical, Interventional Access, Anesthesia and OEM. Partly offsetting those headwinds were positive tailwinds in Vascular Access and other, because hospitals kept seeing strong demand for those kinds of products. When you net those 2 effects together, we estimate COVID represented a $130 million headwind, or roughly a 20% drag on our 2Q revenue growth. Importantly, we took encouragement from the fact that following a tough April, the major global business units hit hardest by COVID showed sequential improvement as May and June progressed. Let me give you the specifics. In April, Interventional Urology's revenue compared with the same month a year earlier was down about 79%. May brought a decline of around 30%, followed by roughly 8% in June. Now turning to Interventional Access. April showed a year-over-year drop of approximately 30%, May came in at approximately 28% lower, and June was down roughly 2%. Finally, our Surgical business recorded year-over-year revenue decreases of approximately 34% in April, 31% in May, and approximately 21% in June. This matches what we anticipated and communicated on earlier earnings conference calls: once states and countries began reopening, Interventional Urology led the recovery. That said, we saw trends improve in Interventional Access and Surgical too, since most hospitals have truly resumed non-emergent procedures. Even though our operations haven't fully returned to their pre-pandemic state, what we've observed heading into July gives us reason for optimism, mostly because it points to additional gains in the business. With that said, we view these recent patterns as positive indicators of an ongoing worldwide rebound, yet we remain prudent, since hospitals in some regions have been stretched thin as COVID-19 infections have shown up again. Because the reach and length of COVID-19 remain unclear, we've chosen against restoring our 2020 financial guidance at this time. Now let's turn to the quarterly results. I'll begin by reviewing revenue for our reportable segment. And unless I note otherwise, any growth rates I mention are calculated on a constant currency basis. During Q2, revenue in the Americas totaled $312.5 million, down 16%. In that region, gains were recorded in Vascular Access and respiratory products, each seeing higher demand tied to COVID. However, those increases were outweighed by weaker results across other product lines. Had COVID's roughly 24% effect on the region been excluded, we figure the Americas would have posted growth of about 8%. Notably, throughout the second quarter, Interventional Urology showed month-over-month gains from April into May and again from May into June, and that favorable trend mostly continued into July. Although we take encouragement from this rebound, we remain watchful given the latest flare-ups and diminished capacity for non-emergent procedures in certain states, Texas and Florida among them. In EMEA, second-quarter revenues came to $131.6 million, a drop of 8%. As in the Americas, the forces pushing growth upward included our vascular and respiratory businesses, which saw heightened demand tied to COVID-19; yet also as in the Americas, those gains across these product categories were more than offset by weaker results in other areas. If we set COVID aside, our estimate for the region's underlying growth is roughly 1%. Now to Asia. Second-quarter revenues reached $67.1 million, down 7.8%.

Liam Kelly

executive
#3

If you strip out what the pandemic did to us, our constant currency revenue would have grown and landed in the low double digits — the same pace we anticipate for this region over the long haul. Moving on to OEM, sales there reached $55.8 million in the second quarter, down 70 basis points on a constant currency basis. As we'd anticipated, the COVID-driven hit to this segment arrived later than it did elsewhere. Anyone who holds Teleflex stock is aware that this unit supplies intricate catheters and surgical sutures to makers of medical devices. The drop we saw in Q2 reflects a smaller volume of orders from those clients, since their business relies on procedures that aren't emergencies. If you set aside the projected COVID-19 effect, this business expanded by about 25%, and that figure includes a 16% gain from HPC. When it comes to buying HPC, integration work is progressing nicely, and I'm quite happy with the way this business is doing under our leadership. Let's turn now to a conversation about our revenues across global product categories. Just as with what I said before about our reportable segments, any discussion of global product category growth will be on a constant currency basis as well. We'll begin with Vascular Access. Our second-quarter top line reached $164.9 million, an 8.8% increase, driven by growth in our central venous catheter and EZ-IO offerings; in our estimation, COVID-19 contributed approximately 5% to the expansion rate of our vascular products during that period. Moving along to Interventional Access. Second-quarter revenue came in at $82.6 million, reflecting a 20.3% decline versus the same period a year earlier. That decrease largely stemmed from the postponement of particular non-emergent procedures as a result of COVID-19. Once you account for a COVID-19 drag of roughly 24%, we estimate that underlying growth was in the mid-single digits. Turning next to Anesthesia. Second-quarter revenues totaled $64.9 million, a 23% reduction compared with the prior year. This top-line decline was primarily the result of reduced demand for our laryngeal masks along with regional anesthesia offerings. In our estimation, COVID created roughly a 22% drag on results for the period. Moving on to Surgical. Sales came in at $67.3 million, a decline of 28.4%, weighed down by softer performance in the ligation portfolio as well as instruments. We estimate a significant 30% COVID-related headwind in the second quarter. That said, as noted earlier, we have seen month-over-month sequential improvement ever since hitting bottom in April. Turning now to Interventional Urology. Second-quarter revenue declined 40.9%, landing at $40.1 million. Our estimate puts the COVID-19-related impact at approximately $58 million for 2Q. Unfortunately, cancellations of elective procedures affected this line more severely than any other product in our portfolio. With all of that in mind, because UroLift is typically performed in an outpatient setting with lower acuity, we expected it to be one of the earliest procedure types to resume as the United States began reopening — and that's exactly what we saw, with month-over-month improvement from April into May, May into June, and June into July. Turning to the final category, our other segment, which consists of respiratory and urology care products, it rose 5.4% to $91.4 million. In our view, the growth this quarter was driven mainly by stronger demand for certain humidification and breathing products associated with COVID-19. If we set aside the projected COVID-19 gain, our estimate is that the remaining portion of the category would have seen a small drop compared with the equivalent quarter last year. That concludes my discussion of how revenue performed in quarter 2. I'll move on now to several updates on the clinical and commercial side. During the second quarter, support from clinical evidence for UroLift continued to expand: findings from 2 studies were shared at the AUA 2020 Virtual Science Event, while results from an additional study appeared in the Canadian Journal of Urology. Back in May, at the AUA 2020 Virtual Science Event, the first study we presented was a meta-analysis looking at how patients' sexual function fared following treatment with the UroLift System compared with medical therapy. The second study analyzed patient outcomes, comparing those from the large Real World Retrospective study against what was seen in the L.I.F.T. pivotal trial and the P.U.L.S.A.R. urinary retention trial. In the first study, sexual function outcomes were compared across 849 sexually active men who had been receiving daily treatment with an alpha blocker, a 5-alpha-reductase inhibitor, or both in combination, and 190 men drawn from combined clinical studies of the UroLift System at the 12-, 24-, 36-, and 48-month marks. According to what the analysis turned up, people who got the UroLift System showed meaningful gains in both ejaculatory and erectile function at the 12-month and 24-month marks after treatment. Through 48 months following treatment, those patients also reported meaningful gains in overall sexual satisfaction. By contrast, at no point did any of the medical therapies produce meaningful gains in erectile or ejaculatory function for patients, and one therapy actually caused a meaningful drop in function. On top of that, when it came to preserving ejaculatory function, the UroLift System beat all 3 medical therapies by a meaningful margin at every time point. Gains in overall satisfaction with sexual life were reported only by patients who received the UroLift System. Patient outcomes from the large Real World Retrospective study were compared with those from the L.I.F.T. study in the second study. During the pivotal trial and the P.U.L.S.A.R. urinary retention study, which looked at BPH patients who depended on catheters, the analysis results showed that across every time point after treatment with the UroLift System, patients in all groups had comparable absolute IPSS scores. The analysis additionally found that safety profiles were equivalent between the non-urinary retention and urinary retention groups in the Real World study, when set against matching groups from control studies. The findings also showed that by the conclusion of the study, most retention patients no longer needed catheters. And finally, a study appeared in the Canadian Journal of Urology comparing how patients treated with the UroLift System experienced their care versus those who underwent tissue ablation via steam injection. That study compared 53 non-retention patients from 2 U.S. On the sites front, when we looked at early data from after surgery, people who got the UroLift System did better than those on resume — things like better sexual function, less interference with day-to-day life, and higher patient satisfaction. Our clinical evidence keeps expanding, and that should help convince the fast followers to get behind UroLift, which is quickly becoming the go-to option as the leading minimally invasive procedure for a very large global market opportunity. Now, on the next slide, which covers important commercial news: we received FDA clearance for the UroLift advanced tissue control system, or ATC. This device makes UroLift better at handling obstructive median lobe, and we plan to run a market acceptance test for it in late 2020. We figure only somewhere in the range of five to ten percent of the market deals with an obstructive median lobe, but even so, this step forward reflects how committed we are to funding R&D so we can extend our lead in BPH. On top of that, because we began seeing non-emergent procedure volumes bounce back over the course of Q2, we chose to launch our pilot national DTC campaign at the start of July, building on what our regional DTC work had already achieved. That national effort will run from July through December, and DTC's strategic role is huge, given that about half of the 12 million men who get treated for BPH believe prescription drugs are the only route available to them. Now, on the subject of timing.

Liam Kelly

executive
#4

When we look at the digital DTC work we did in our region, it showed us that patients were really engaged during June, and clinicians were feeling good about it too — that combination made us feel solid about the July launch. It's early days yet, but the early reaction from patients has been quite strong: we've seen meaningful growth in call volume and big jumps in traffic to urolift.com compared with the weeks before we launched. Doctors have been giving us very favorable feedback as well. In fact, UroLift is out in front when it comes to BPH, and it's been quite a while since any BPH brand has connected with patients directly in a way that really matters. On top of that, at the close of the second quarter we filed UroLift 2 for 510(k) clearance from the FDA. One more thing — I want to say congratulations to the interventional urology team, since they've now treated more than 200,000 patients with UroLift. That's a big milestone, but with DTC running in the U.S., roughly 2,700 urologists who've been trained, and significant market launches on the calendar for the coming years, we've barely gotten started when you consider the roughly 100 million men around the world who are thought to have BPH. Now some clinical news from our Interventional business unit. We've just started enrolling patients in a prospective single-arm IDE trial that aims for 150 patients at about 15 sites in the U.S., looking at how Teleflex coronary guidewires and specialty catheters perform in chronic total inclusion percutaneous coronary intervention procedures. This trial is going to assess how the full lineup of Teleflex complex PCI products performs in chronic occlusive coronary disease, which happens to be the toughest PCI setting there is. We see PCI as a space with high growth inside the Interventional Cardiology segment, and we'll keep putting money into areas that raise our weighted average market growth rates down the road. All in all, we're continuing to fund clinical and commercial catalysts that support our goal of upper single-digit revenue growth in a normalized environment. That's everything I had prepared. At this point I'd like to hand the call over to Tom, who will walk us through our second quarter financial results in more detail. Tom?

Tom Powell

executive
#5

Thank you, Liam, and hello everybody on this morning's call. With the company's revenue results already covered, I'll pick things up at the gross profit line. Adjusted gross profit for the quarter came in at $305.8 million, compared with $376.6 million during the same quarter a year ago, a drop of roughly 19%. Adjusted gross margin for the quarter was 53.9%, down 380 basis points relative to the year-ago period. The margin contraction was mostly driven by COVID-19-related effects, among them an unfavorable product mix, reduced sales volumes and elevated manufacturing costs. For the quarter, that mix effect was substantial. COVID-19's negative revenue effect skewed toward products carrying higher gross margins, such as UroLift, Surgical and Interventional Access. All told, we estimate COVID-19 cut our adjusted gross profit by about $100 million during the quarter. With revenue and gross profit both lower because of COVID-19, we keep searching for ways to offset the hit to earnings while simultaneously preserving Teleflex's capacity to snap back quickly once non-emergent procedures return. Accordingly, our operating expense cuts are generally aimed at areas that don't generate revenue and are discretionary by nature, such as savings on meetings, travel, and management variable and performance-based compensation. Thanks to these efforts, we estimate that operating expenses came down by roughly $35 million in the second quarter. Although we anticipate that the steps we've taken will keep producing OpEx savings through the back half of the year, the biggest quarterly benefit by far will land in the second quarter. Adjusted operating profit was $123.9 million, versus $164.7 million a year earlier, a decline of approximately 25%. Operating margin for the second quarter was 21.8%, a drop of 340 basis points year-over-year, caused by the gross margin declines and lost operating leverage, partially offset by lower operating expense. Net interest expense for the quarter totaled $15.5 million, roughly 24% below the prior year quarter. That reduction in interest expense mainly reflects lower interest rates on our variable rate debt, partially offset by higher average debt balances in the second quarter of 2020 compared with the prior year period. During the quarter, we acted to strengthen our liquidity further by issuing $500 million of 8-year senior notes at 4.25%. We used the proceeds from that note issuance to pay down revolver borrowings. Turning to taxes, our adjusted tax rate for the second quarter of 2020 was 15.8%, compared with 13.4% in the prior year period. The increase in our adjusted tax rate year-over-year stems mainly from a smaller benefit from stock-based compensation than in the prior year period. At the bottom line, adjusted earnings per share for the second quarter fell 27.4% to $1.93. That result includes an estimated COVID-19 headwind of $1.18 along with a foreign exchange headwind of about $0.04. I'd now like to talk about the workforce reduction plan we introduced recently. In Q2 2020, we put a workforce reduction plan in place aimed at boosting profitability by simplifying some sales and marketing functions in EMEA and certain manufacturing operations in OEM. Our estimate is that aggregate pretax restructuring charges will land between $10 million and $13 million, mostly termination benefits, which will also mean future cash outlays. We anticipate incurring the bulk of those charges before 2020 ends. When the plans are fully carried out, we project annual pretax savings between $11 million and $13 million, and we expect those savings to start in 2020. I'll also give a summary of every restructuring and cost savings program currently underway. Adding in this newest workforce reduction plan, expected savings across all programs come to between $59 million and $72 million. Roughly 1/2 of those savings should be realized in 2020 and 2021, with the other 1/2 coming over the period 2022 through 2024. Because of this, we have solid visibility into margin expansion that doesn't depend on revenue in the near future; it also strengthens our confidence that our earlier LRP financial targets of 6% to 7% revenue growth, 60% to 61% gross margin and 30% to 31% operating margin stay the correct objectives for Teleflex; the only question is when, not if, we get there. Moving briefly to a few balance sheet and cash flow highlights. In the first half of 2020, cash flow from operations came to $134 million, compared with $157.3 million in the same period a year earlier, a year-over-year decline of $23.3 million. That decline stems from a $10 million pension contribution we made in the first half of 2020 that wasn't made in the first half of the prior year, plus a $54 million rise in first half 2020 contingent consideration payments relative to what was paid in the first half of 2019. On the whole, the balance sheet is still in good shape. When the second quarter closed, our cash balance stood at $553 million, versus $406 million when the first quarter ended. Net leverage at quarter end came in at about 2.6x, which gives us comfortable headroom relative to our covenant requiring us to stay below 4.5x. Finally, we face no near-term debt maturities of material size; that wraps up my prepared remarks. I'd now like to hand the call back to Liam for closing commentary.

Liam Kelly

executive
#6

Appreciate that, Tom. Before we finish, there's a matter I should flag that you'll see reflected in the 10-Q we're submitting today. This past June, NeoTract — one of the businesses we own — began producing records and details after getting a civil investigative demand from the U.S. Department of Justice, working through the United States Attorney's Office for the Northern District of Georgia. What that demand asks for is documentation and information about interactions with one particular NeoTract customer, along with specific rebate programs that were extended to that customer — all connected to the DOJ's probe into that same customer. Also in July, we were informed by the DOJ that, separate from the customer probe, it had opened an inquiry under the Civil False Claims Act that extends to NeoTract's business activities in a broader sense. To foster adherence to the Anti-Kickback Statute, the False Claims Act and other relevant statutes and rules, we maintain policies and procedures; and while the company intends to work with the government on its investigation and its information request, we will fight hard to defend our programs, practices and conduct, since we consider them to be lawful and in line with the best practices and standards in our industry. Right now, we have no reasonable way to foresee the duration of this matter, the scope it may ultimately cover, or what the final outcome will be. Wrapping up, our second quarter performance came in strong, since having a varied portfolio cushioned some of the blow from COVID in April, and case volumes started climbing each month from May through July; even so, forecasting the exact form and length required to gauge how quickly things bounce back is still tough. And although there will be some unpredictability across the coming quarters, our assurance in the strength of our core long-term basics hasn't wavered, and we continue to see significant potential down the road to support those we serve. Our team's ongoing priority is to support the bulk of hospitals that are still performing procedures, even as we keep a careful eye on those particular areas where operations have paused for now. We keep adjusting how we operate and are seizing chances to place more weight on digital solutions, for our own teams and for the clients we serve. We'll run things in a disciplined way and remain committed to capturing the future value that our worldwide product lineup offers. To wrap up, I want once more to express gratitude to every one of our staff members who keeps producing, shipping, and backing the goods needed in the battle against COVID-19, with a focus on honoring what we owe to patients, clinicians, communities, and shareholders. That brings my prepared comments to a close. At this point, I'll hand things over to the operator so we can move into the question-and-answer portion.

David Lewis

analyst
#7

Thanks, Liam — two things from me this morning. First up, clearly, the key topic everyone's focused on is NeoTract, so I've got a few questions there. In July, did NeoTract post growth compared with a year earlier? There are also a few trends worth checking for July. One is resurgence — did resurgence have any effect that you noticed? And then, clearly, the DTC campaign kicked off. So was there any effect from resurgence, or any gain from DTC, and like I said at the start, did NeoTract grow during July? Then one quick follow-up.

Liam Kelly

executive
#8

All right, David — many thanks for that. To walk through the NeoTract trends we observed, clearly, April brought a large drop, 80% lower, then 30% lower in May, and after that we kept seeing improvement in June, when we were 8% lower. Heading into July, positive momentum with the UroLift product kept building. I'm happy to say it turned green during July as more practices reopened. Some practices did shut down in particular areas, really on a county-by-county basis in certain areas, especially Texas and Florida. But offsetting that, you had practices reopening in New York, New Jersey and Pennsylvania, so it balanced out. On your DTC question, it was almost too soon to detect any DTC effect at this point, with patients booked. Still, we saw substantial foot traffic on the test we ran. We actually needed to add more call center staff to handle the calls, and we saw a big jump in traffic to urolift.com because of the initial DTC. It's early, David, but the signs for the UroLift product are very positive.

David Lewis

analyst
#9

All right. So UroLift expanded even with the July resurgence, and it seems like DTC's effect lands more heavily later on in the quarter. Then let me wrap up with my final question, Liam. The thing is, most of your competitors aren't quantifying any COVID-19 hit, while you are; that points to organic growth of roughly 7%, 7.5%, though against a really tough comp; so we're talking about a few points of accelerating momentum. When you step back and look at your whole business in Q2 on an underlying basis, where would you say that strength, or that pickup in momentum, was concentrated the most?

Liam Kelly

executive
#10

Thank you, David. I'd first note that the reason we provide that degree of detail and clarity to the investment community is to give them greater transparency into the business and into how we expected the COVID impact to hit us. Over the course of the quarter, I'd say the momentum showed up in a handful of places; we keep gaining within the underlying business in Interventional, Urology, and UroLift clearly keeps delivering strong results. If you strip out COVID, our estimate is that UroLift expanded by about 44%. So that's a strong, solid showing from UroLift once COVID is excluded. Clearly, the OEM business on an underlying basis, absent the acquisition, did extremely well. EMEA came in a bit soft, though a distributor order slipped out of the quarter; factoring that in, I was in fact fairly happy with how EMEA did too. And naturally, our Vascular business keeps expanding and gaining share, just like their Interventional business. So it was fairly broad-based, David, but those are the primary drivers.

Larry Keusch

analyst
#11

All right. Liam, it's clear the pandemic taught you quite a bit regarding how resilient this business can be. So I'd like to know, what's your view on how sustainable this growth will be going forward? And are there places you can now identify where putting in more money could keep that same growth pace going, or maybe even speed it up?

Liam Kelly

executive
#12

Yes, thank you, Larry; and I believe that, yes, a wide-ranging portfolio that isn't too dependent on procedural volume has shown us plenty about its staying power. Obviously, the UroLift product will be a key focus for faster expansion and future spending. As I mentioned during my prepared remarks, penetration has barely begun. And we — now that the UroLift 2 510(k) has been submitted, once approval comes through, we can keep making headway in Japan. Our clinical trial is underway in France, and further out we see a chance in China. And in North America, we've barely begun. Of the 12,000 urologists across the United States, just 2,700 have been trained so far. So there's meaningful growth from American expansion abroad. On top of that, you'll have picked up on today's call that we keep putting money into clinical evidence at a broad level — reaching past even the Interventional Urology business unit and the UroLift product, through the CTO trial we said we're moving ahead with inside Interventional. We view that as a way to grow our product's market potential by another 70,000 cases, roughly 7% or 8% of PCI cases fall into that CTO category; so we consider that a solid opportunity; and furthermore, we'll keep investing to support our penetration into PICCs, especially across North America, and keep gaining share inside that portfolio; so those are, broadly speaking, the places where we foresee future investment. And DTC, it's still very early, Larry; but should DTC deliver what we believe it's capable of, I don't see any reason it wouldn't keep going across a multiyear stretch.

Larry Keusch

analyst
#13

All right. So it seems as though you have confidence in how long the company's growth can last as it emerges from COVID? That's kind of question 1B. And then maybe this one's for Tom. Once more, if I consider what Liam said in his answer and the chance to put more money into investment, I realize you mentioned the LRP objectives remain the appropriate goals for the company. But should we figure that margins might take somewhat more time to reach those objectives, assuming you have chances to invest? And I suppose the latter portion of that question is, when you consider the expense reductions that you've achieved throughout COVID and you're operating with greater efficiency. I realize you stated a portion of that will begin returning once you start spending. But is there — do you have expense reductions available that would prove more lasting as you look forward?

Tom Powell

executive
#14

All right. Well, definitely, when we consider putting money toward the future alongside margins, I'd begin by saying, concerning margins, we'll restate our view that we regard the 60%, 61% gross margin and 30%, 31% operating margin as the proper goals. We think this business possesses the ability to reach that level and to keep pushing margin growth. What we truly need to determine is the timing; and a crucial element of that margin growth involves mix, and a crucial element of the mix involves UroLift; so when that business keeps delivering, and we observe an improved trajectory, we'll gain a clearer picture of the timing around reaching those margin goals. When we consider investment, we'll weigh growth against margin goals, and we'll keep seeking methods to generate efficiency, so that we can pay for the investment. Yet we don't anticipate a significant investment that pulls us off those goals. In reality, what we anticipate as we put money behind UroLift is a strong margin narrative; it ranks among our best opportunities for gross margin and operating margin. So we regard that as a possible chance to keep pushing margin growth by investing. Regarding the expense reductions, much of what we've removed during this year stems from — when you consider it, we're keeping roles unfilled, actually, hiring is challenging throughout this period, we have T&E, we have certain decreases in management compensation; so when we consider moving ahead, many of those expenses will reenter the system. When we consider which of the cost savings are going to stick, I'd say the new organizational restructuring will definitely generate some savings that are permanent. But when it comes to a lot of the cost reductions we've removed this year, those are costs that, for the most part, we expect to put back into the system once we get into 2021.

Richard Newitter

analyst
#15

Starting with UroLift and what was said about July's recovery — I'd like to know where exactly you're observing cases picking back up. My understanding is you mentioned certain shutdowns. Is that really coming from the supply side, meaning providers are the ones closing, or does it lean more toward the patient side, with people simply less willing to go out and pursue treatment? The reason I ask is mainly to gauge how procedures done in-office, at an ASC, and in an in-office setting at a hospital might each perform when the virus situation is better informed and understood; and whether we'd actually witness the same sort of impact as during the first wave. If we could use July as the reference point for your answer, that would help. On top of that, I'd like you to break down how much of that volume comes from working through existing backlog versus fresh growth generated by the office.

Liam Kelly

executive
#16

Rich, I appreciate the question. The way we see it, it's mainly providers shutting locations in specific counties and states, and they're doing so because the state directed them to. Our research — we looked at our own customer base — showed us something. What we took away from it is that patients, our patients, are actually pretty at ease visiting any of the 3 sites of service, since the procedure takes so little time — 1 hour, and it's minimally invasive. One thing I want to emphasize is that general anesthesia isn't required here. That means no aerosolized gas gets administered to the person during their procedure — instead, it's lidocaine, or possibly a block, depending on what they choose. And from what we've observed, people have felt at ease receiving the procedure across all three locations where it's offered. Honestly, what caught me off guard was how ready patients were to visit the hospital; their confidence level there matched what they felt at the office and the ASC — that genuinely surprised me a bit. On top of that, we're quite optimistic about how patients are moving through the hospital. Not long ago I had a conversation with the head of a large system, and his worry was that a bigger health care problem will emerge if people stay away from hospitals. He came up with a saying—it's his, not mine. Rather than using the word pandemic, his term was "the pan didn't"—didn't get this procedure, didn't get that procedure. And as I mentioned, what concerned him was that skipping hospital visits will create consequences further down the road. Even so, it gives me encouragement that patients are ready to come in and undergo UroLift procedures.

Richard Newitter

analyst
#17

All right. Then let me just confirm something — I appreciate how thoroughly you tried to put numbers around COVID's effect. Working backward, I calculate roughly a 7% organic growth rate for 2Q, actually slightly below that at 6.6%, once you strip out around 1.5% that came from the inorganic HPC piece. First, is that the right way to look at it? Second, I believe you said certain orders got delayed. Could you perhaps put a figure on how much that weighed on the quarter? And assuming my math holds, would removing that have pushed the organic growth rate up?

Tom Powell

executive
#18

Yes. Rich, you're giving the M&A more credit than it deserves. Our organic growth would actually have come in above that figure. As for the delayed orders, that happened in Europe and amounted to somewhere around $3 million to $4 million. Those were distributor orders that got pushed into Q3. If you take a step back and consider our growth overall, in the first quarter, leaving aside COVID's impact, we posted growth of just over 8%. In the second quarter, growth was 8%; and I'd also like to point out to the investment community that quarter 4 gives us 2 extra days, which acts as a catalyst in the back half of the year. And clearly, with the DTC and UroLift combined — our two fastest growing assets — we view that as another catalyst in the back half, and it was very encouraging to see the UroLift product turn green in July.

Shagun Singh Chadha

analyst
#19

I've been thinking about what July's patterns might mean for Q3. Is it possible to get roughly flat growth in Q3 on a year-over-year basis? Also, do you continue to anticipate normalization in Q4? Then I have one more question after that.

Liam Kelly

executive
#20

Shagun, many thanks for asking. As July has unfolded, we feel fairly encouraged by the clear though moderate strengthening observed across all our businesses during the month. I don't want to lead the investment community astray by claiming that for Teleflex overall, the opening weeks of July show positive growth, since that isn't the case. It remains negative, yet the result is improved compared with what we'd witnessed. Giving guidance is genuinely hard for me beyond — even regarding whether the third quarter should move — we withdrew our full-year guidance purely because of COVID-related uncertainty. That said, I can share that I and management feel far better now, sitting here today in late July, than we did in late April on our first quarter earnings call, and our confidence has grown considerably that this is starting to resemble a V-shaped sort of recovery more than anything else, rather than a U. I'd add as well that from talking with hospital CEOs, they have solid plans in place, in case a second wave arrives, to try to avert what occurred during the first wave when procedures were cancelled, because, as I mentioned before, of the lasting effect that will have on people.

Shagun Singh Chadha

analyst
#21

That's a big help. As a quick follow-up about the national pilot DTC campaign — our research indicates the volume lift might land around 20% or so. Is that a reasonable figure, based on what you've observed in certain DTC regions? Also, I'm curious what conversations you're having with urologists so they can be strategically ready for the extra patient flow once it arrives?

Liam Kelly

executive
#22

Yes. Before starting the DTC, we reached out broadly to urologists. Typically, what we request from urologists is that they keep some flexible capacity in their practice, so that when patients click on our website or phone our call center, we're able to steer them toward urologists who have room. One crucial thing is that a patient must get a call back from a clinician within 24, 48 hours; another crucial factor is that the appointment needs to be booked within roughly 4 to 6 weeks. It's very early for us to gauge the effect on the uptick, Shagun. I wouldn't question your methodology. Your track record has been pretty solid up to now, so I'd rather not speculate there. Still, we can't yet reach any firm conclusion on this—one more quarter of uninterrupted DTC would give us a clearer picture. As for the DTC campaign, it kicks off in July and, provided COVID doesn't flare up badly a second time, it will continue from July all the way to December 31. That's what we're planning to do. Shagun, that first rollout was also restricted in scope, since we only used two out of the four TV networks we intended to target — the goal being simply to try out our call center. I'm genuinely pleased we took that approach, because demand rose so sharply that we had to bring in more staff for that call center. On top of that, I'd note that the response from patients who saw the commercial, as well as from the urologist community, has been extraordinarily favorable.

Matt Taylor

analyst
#23

The first thing I wanted to ask about was those underlying growth rates outside of COVID during the second quarter that you described as encouraging. Could you explain how you arrive at that estimate, since I'd imagine it's quite difficult to do? And are you still seeing that type of robust high single-digit underlying growth for the company as we go through July?

Liam Kelly

executive
#24

I'll take the July growth rate, and I'd like to ask Tom, if that's all right, to handle the methodology. He's in a better position for that. Regarding July's growth rate for the whole company, it got better; so in effect, I believe we can say the company-wide growth rates were at minimum in line with Q2. That answers your question about July's growth rates. Clearly, COVID had less of an effect in July. So you'd expect that if that's true, the growth rate for the company as a whole ought to improve. But once more, like I mentioned before, I don't want to give the investment community the wrong impression. As a whole company, we aren't in positive growth yet across the first few weeks of July, though the trend is improving; and Tom, would you mind walking through the methodology?

Tom Powell

executive
#25

Okay. To discuss the overall strategy — and naturally, there are variations across each business unit — basically, we started out with the budget and forecast projections we had originally. After that, we made adjustments for deviations we already knew about. For example, we examined what the trends looked like before COVID broke out, and how our performance stacked up against what we had projected. We also considered shifts in the competitive landscape, whether there was a situation in which we might gain share or lose share. We reviewed programs that had been canceled, events that had been canceled, CMA programs that had been postponed, and we put numbers to that. We examined other things too, like backorder status and how that changed, the ordering patterns of distributors, and messages from customers about orders being pushed. So basically, this amounted to an analysis of trends, adjusted for activities we already knew about. And whatever gap existed between the budget, once adjusted for those activities, was entirely ascribed to COVID. Of course, we understood the methodology lacked precision, but what we aimed to do, as an organization, was get a better grasp on what we believed COVID's impact to be, and we figured that as the investment community, we ought to pass that information along to you too.

Matt Taylor

analyst
#26

All right. Okay, and next I was hoping you might take a moment to discuss the DOJ investigation. Do you expect that will affect what's happening with NeoTract? From what it sounds like, it began with a single customer, but the scope has widened somewhat at this point. Is any commercial impact showing up yet?

Liam Kelly

executive
#27

As you can imagine, Matt, we're at a very early stage, and there's only so much we're able to share right now. My belief is that no commercial impact has appeared as of yet. You likely know that matters like this often stretch out across a stretch of time. So my expectation is that things will remain the way they are. Should it move forward, we'll of course give additional updates at the proper moments. One more thing, Matt — I'd like to restate that we keep policies and procedures in place to ensure greater compliance with the Anti-Kickback Statute, False Claims Act and every other law and regulation that applies. And we'll work alongside the government's investigation and any information request. We'll also fight hard to defend our programs, our practices and our conduct, which in our view are lawful and consistent with the best practices and standards in the industry.

Matthew Mishan

analyst
#28

How much coordination exists between the DTC effort and your urologist partners across the different regions? It also appears that the volume you might be generating for those partners could be quite beneficial. What's your outlook on how that relationship and channel will develop for you moving forward?

Liam Kelly

executive
#29

Clearly, our ties to the urology community are excellent. At times there's a slight worry that running a broad DTC campaign could alienate your customer. That's certainly the last thing we'd ever want. That's why we've communicated extensively with the urology community regarding this campaign. Our aim is better patient outcomes. I believe urologists share that same aim of better patient outcomes. Better patient outcomes simply aren't achievable unless patients are informed about the optimal procedure for benign prostate hyperplasia. So to me, it's a genuine partnership. My sense is that the urologist community backs what we're doing. Their feedback tells us they're backing it. This strikes me as genuinely beneficial for patients. It benefits the health ecosystem too, since treating a man with BPH becomes less costly overall when he's on pharma. That crossover point arrives at 2 to 4 years, regardless of whether it's a generic or a branded product. So because of that, I view this as sound practice for the whole ecosystem, boosting awareness and delivering strong patient outcomes with no sexual dysfunction using the finest treatment available on the marketplace for BPH.

Matthew Mishan

analyst
#30

All right. Then, Liam, let's pivot for a moment. Suppose we find ourselves in a climate of slower growth as we leave 2020 and enter 2021. What do you believe that implies for M&A on a wider scale? And how do the more appealing assets tend to behave under those conditions?

Liam Kelly

executive
#31

Well, heading into 2021, my own view is that growth would actually work the other way, since you'll face a far simpler comparison across Q1 and Q2. Initially I figured you'd see a bolus of extra procedures during the latter half of this year — we'll have to wait and see whether that materializes. With some of the resurgences, it might not occur until 2021 arrives. When it comes to how this affects M&A, my sense is that for businesses such as Teleflex, the way we approach M&A is not going to shift. What we seek is new, innovative technologies; we're quite drawn to technologies that are clearly single-use, that deliver excellent patient outcomes, that carry a strong health care economics argument, that broaden our growth and margin profile as an organization, and that ultimately make patient outcomes better. So for companies like Teleflex and the assets we're considering, I doubt this will matter much. And clearly, by the close of this quarter, our balance sheet, as Tom described, was in very solid condition. Net leverage sits at 2.6x. As we witness a positive recovery from COVID, I believe the M&A landscape ought to present opportunity for organizations such as Teleflex.

Anthony Petrone

analyst
#32

I trust everyone is doing well and staying healthy. I have several questions regarding UroLift — a few follow-ups — and then some brief ones about MANTA and EZPlaz. So, starting with UroLift, can you tell us the latest figure on the number of physicians who have completed training? And if you can, what share of patients originate from drug therapy? Liam, you pointed out that the study clearly demonstrates advantages over drug therapy, and that represents the largest population to pull from. So what's the current status regarding patients transitioning from drug therapy to UroLift? And ultimately, where does this lead? How large can UroLift become within the BPH space? After that, I'll ask my follow-ups.

Liam Kelly

executive
#33

Alright, Anthony. Everyone here is doing fine, thanks, and I trust things are good on your end as well. Now, on the training front — clearly, during Q1 we'd trained slightly fewer than 120 urologists. Then when Q2 arrived, we trained a bit under 70 urologists once more. To put that in perspective for you, Anthony, April saw us train only 7 urologists, since the majority of them were short. So, as you can imagine, once May and June came along, we scaled back up toward typical urologist training levels, and we're now able to get into urology practices to conduct that training. That has been a genuine bright spot for us.

Anthony Petrone

analyst
#34

Anthony, thanks for that. So, on the question of capturing patients from drug therapy — is there any way to figure out where things stand right now?

Liam Kelly

executive
#35

Honestly, Anthony, there really isn't. Back when we were doing the pivotal trial, it was a lot simpler. My sense is that it hasn't shifted all that much. Roughly 70% of the patients we see are either coming off the drug or fall into the drug category. And I don't think — from what I hear anecdotally when I speak with urologists, and from what the Interventional Urology team tells me, that figure has stayed fairly consistent over time.

Anthony Petrone

analyst
#36

Anthony, glad that was useful. Now, moving quickly to the MANTA launch — is there any update, plus the EZPlaz BLA filing, specifically regarding schedules and the way COVID has affected them?

Liam Kelly

executive
#37

Of course, Anthony. As for MANTA, it clearly took a hit from COVID. For some background: in North America, our main market, MANTA dropped nearly 40% during April, yet by May and June it had swung to growth. Once hospital access opened up again, that upward movement carried on through July. So what I'm seeing there leaves me fairly optimistic. Turning to EZPlaz, we've had a few calls with the Department of Defense along with the FDA; so far, that in-person meeting hasn't taken place. It ought to occur during this quarter. Purely owing to COVID, we've even managed to arrange it remotely. The Department of Defense is eager to obtain the product, and they've been in discussions with us, and with the FDA, about the pathway we could pursue toward an emergency use authorization as an initial step ahead of the BLA. There will be more updates on this, Anthony, once we receive further details. Still, I regard it as encouraging — at minimum, I take it as encouraging that the Department of Defense is advocating for an emergency use authorization so the product reaches the troops.

Chris Cooley

analyst
#38

I'll go ahead and ask both of mine back to back. Regarding the UroLift product line in the back half of this year, clearly you've got the ATC launch coming right at the close of the year, plus the national DTC effort and the scaling up. I realize you typically steer clear of commenting on specifics at the individual product level, but would it be unreasonable to imagine UroLift still delivering a flat to slight upward path during 2020 before gaining steam in 2021? Then, stepping back to the broader picture, I'm somewhat curious — you mentioned cutting staff in a few chosen markets. Yet, after watching the past really 3 or 4 months with COVID-19, I'd like to know what more lasting lessons you've drawn regarding simply how you run things that you believe will turn Teleflex into a leaner operation down the road? Not merely from trimming headcount, but perhaps your approach to the market, perhaps how you procure raw materials. I'm just sort of wondering what measures are being implemented right now that will show up as an upside possibly during '21 and later as conditions hopefully return to something more normal?

Liam Kelly

executive
#39

Thanks, Chris. Well, to start with, regarding UroLift, I'd rather not dive too deep into what we anticipate for the entire year. Clearly, we withdrew guidance and there's such enormous uncertainty with COVID, it's tough to predict. Still, I mean, the wonderful part is that any journey starts with that initial move. And that initial move for us is achieving positive growth in July; so it has edged just barely into positive territory during the opening weeks of July, which gives us heart; and that encourages us that we ought to have, without question, positive growth as we head into Q4 and then spring into 2021 at a more normalized pace of strong, steady expansion. Since each dollar of growth on UroLift, as all of us recognize, is a valuable dollar for Teleflex given the margin structure behind it. Another point I'd add is that we've also got the UL2 filed for 510(k) at the close of June, which ought to assist us with that margin structure once we reach 2021 as we introduce the UL2 to the urologists. As for the staff reduction, that reduction from a sales and marketing standpoint in Europe is truly aimed at growth. What we're doing is redirecting resources toward our quicker-expanding assets, such as the UroLift, such as the Interventional Access portfolio, such as our Vascular portfolio. And I believe that's work we're undertaking to fuel growth inside the business and likewise resize that organization to match that growth. On our longer-term lessons, I think there are a handful. From what I can tell, we've got a company that has performed extremely effectively and shown tremendous flexibility and efficiency while not operating out of an office. Our interaction with customers has been at a really elevated level. A complete BPH Summit for the UroLift product was conducted by us in a virtual format; the AUA was attended by us virtually as well. Virtual sessions covering MANTA within the Interventional business were delivered by us. And regarding a number of our go directs that we've been working through, during the COVID crisis we've carried out virtual due diligence on a few of the smaller ones. So a decrease in our T&E overall over a longer horizon, along with our office space costs, is something I believe is going to occur. Plus, fewer wins — we're able to make our sales force far more efficient by cutting out windscreen time and leveraging technology to place them before customers virtually; so there are many learnings and many changes that I believe will benefit us over the longer term in order to drive — to keep driving our top line growth as efficiently as we can.

Matthew O'Brien

analyst
#40

Liam, I want to stay on the UroLift topic, and I apologize for keeping us on this track. But at the start of the year, you indicated you expected roughly 25% growth for that franchise. On an adjusted basis, the first 2 quarters would have come in well above those figures. What are you observing out in the market that's pushing you past what you'd originally anticipated entering the year, again on an adjusted basis? Are you finding that physicians are drawing significantly more patients into their offices because UroLift is now something they can offer? Is that kind of dynamic at play? Is there anything like that you can really point to? And as you bring UroLift 2 to market, likely in late 2024 and into 2025, how will you pull that off smoothly without creating disruption to the business, given the DTC tailwind you'll probably have? And then I've got a follow-up.

Liam Kelly

executive
#41

Of course, Matt. If it's alright with you, I'll address the second part first — the UL2 launch. The basis for our confidence that no disruption will occur is that it functions quite similarly to the UL1, resembles the UL1 in being a cartridge system, yet carries every benefit of the UL1 along with excellent patient outcomes, and it's simpler to operate. Training a urologist to transition from a UL1 to a UL2 requires only 5 cases. That amounts to fewer days of work within a urology practice to make the switch; therefore, for all those reasons, I don't expect any disruption. Additionally, adopting the UL2 benefits Teleflex, and the urologist benefits too, since they'll achieve the excellent patient outcomes. They've consistently had no sexual dysfunction, strong IPSS scores, and so forth. Beyond that, it will lower their carbon footprint as well as their clinical waste. So for those practicing in a urology office setting, it will render their practice somewhat more profitable. As for the growth rate itself, we're highly encouraged by it. Historically, I'd say we've tended to be fairly conservative right from the beginning when setting our projections for the UroLift product. And I believe most people also felt 25% was somewhat conservative. Even so, the reason we typically stay conservative is that we're shifting from the early adopter phase into the fast follower phase. What we've observed is that fast followers are now embracing the technology more rapidly than we'd initially anticipated. And provided we can sustain that strong effort and momentum, I think that bodes well. The accelerators that have helped us reach this point are the investments we've made. During Q4, instead of holding off until Q1, we put money into the sales force, and we keep spending on DTC, on product innovation, and on clinical papers so that this technology reaches a wider group of urologists than it does now. Yet we still have to acknowledge that the market is enormous; as I mentioned, up to now we've completed 200,000 cases out of 100 million men.

Matthew O'Brien

analyst
#42

Understood. That's useful context, Liam. I'd like to shift focus to Vascular Access for a moment. COVID has been a tailwind for that segment, yet you also hold a number of highly differentiated products in that portfolio. So my question is whether COVID has wiped out what makes those offerings distinctive, or whether it might actually accelerate that business meaningfully across the coming 2 years. Alternatively, as conditions settle down or the pandemic winds down, could you run into some revenue pressure since you're treating fewer COVID patients and so forth?

Liam Kelly

executive
#43

Yeah. Within the Vascular business unit, the biggest winner from the COVID pandemic was our CVC franchise. As you're aware, Matt, we lead the market. On central venous catheters in North America, our share is near 90%, driven by our coating technology and the way it reduces infections among patients and in hospitals. Historically, the piece we've been expanding is our PICC portfolio, again thanks to our coating technology. There's a fascinating dynamic at play during COVID. That dynamic is that demand for CVCs has risen since more patients are in intensive care units. A second dynamic is that we can't win over as many large customers as we used to, because hospital access is impossible during COVID. So once you emerge and conditions begin to stabilize, 2 things will happen. CVC growth will return to a more typical level, roughly 4%, and PICC growth will begin to accelerate as well. Taken together, Matt, this ought to be a slight headwind rather than a tailwind, since our CVC franchise dwarfs our PICC franchise by comparison, but still a slight headwind as things normalize. That said, I think what you'll observe in the back half of the year is hospitals ensuring they hold sufficient CVC kits in case a second wave arrives, to help them cope; so the headwind might not show up until 2021. By then, other parts of the business that took a hit will more than compensate through easier comparisons, especially in Q1 and Q2; so that's my expectation for how this unfolds across the next 18 months, roughly speaking.

Mike Matson

analyst
#44

I suppose I only have two. So to begin, regarding the OEM segment, it seemed like COVID had quite a substantial adverse effect on you; yet I'm curious whether there might be some possibility of a delay there, given that your device clients might be working through some inventory reduction, if their stock levels finished the second quarter on the high side? And then, I suppose, a further question connected to inventory reduction. I realize that when it comes to your overall business, distributors now account for a far smaller share of revenue. But do you have any sense of how much inventory currently sits with those distributors?

Liam Kelly

executive
#45

Yes, Mike, many thanks for those questions. I'll begin with OEM and the delay issue. So what we observed in our OEM segment as the quarter progressed was that April and May showed positive growth for OEM. After that, June came in at negative 13%, producing a total quarter of roughly negative 0.7%, and that was unquestionably the delay that struck us during June. Now, as we've moved through July, I'd say that 13% negative delay has gotten better. Once more, I don't wish to give anyone a false impression that it has entered positive territory the way UroLift has, but the negative delay has grown smaller. So we always anticipated a delay with OEM, because as you note, that's simply how this business works; so I think that's what has taken place in the OEM segment. When we turn to our distributors, and once again, I'll begin with the tracings for those distributors. And as you're aware, I always examine the tracings to grasp what's going on with our business as a whole. And the tracings for our end customers across the first half of the year nearly precisely match the results we're reporting in our published figures. So that tells us it's consistent. And what we observed in the quarter was an extremely, extremely slight rise in inventory, but extremely slight, Mike. You could nearly regard it as neutral sales-in versus sales-out for the quarter.

Kristen Stewart

analyst
#46

I want to express my gratitude for how much detail you gave us during this call. It's truly appreciated. I'd like to return to that NeoTract item in the 10-Q. It's good that you're addressing it today, before the filing, in a proactive way. A few questions, then. I suppose, what makes you feel comfortable enough that there won't be any — I realize this has been asked already, but I'm having trouble with how confident you are that there really won't be a commercial effect. And I'm wondering why only one customer is involved. That's just something I've never encountered. Is there a way to frame how big that single customer is by comparing it to a bigger customer? And what's the actual danger that this extends into other customer arrangements? Because one of the key — not the key, but one aspect of what makes UroLift beneficial has always been its reimbursement advantages. So my worry is that perhaps something involving the rebates or the reimbursement side is at play. Naturally, the product's clinical benefits speak for themselves and have always been recognized, and you have plenty of clinical data, but my concern is that when your competitors start using this as a marketing talking point, there could be some commercial consequences. So I suppose, where does your confidence come from that there won't be a more significant commercial effect?

Liam Kelly

executive
#47

Well, to begin with, and as you know, Kristen, it's extremely early, and there's a limit to how much we can discuss or reveal. Still, it's quite uncommon, in my own experience at least, for a company to take a situation like this and turn it into a marketing tool aimed at another company. And I believe regulators and authorities would not view that favorably. Another point: reimbursement isn't the responsibility of the Attorney General's Office. A different organization handles reimbursement. And reimbursement is fundamentally determined by how much time the procedure takes, what the procedure costs overall, and what benefit the patient receives from it. My remarks about commercial impact rested on the idea that a longer stretch of time will be needed for information to flow between our company and the Attorney General's Office before we can genuinely understand whether any commercial impact exists. But I'd be careful not to connect the disclosure to anything related to reimbursement for a product of this kind — those are 2 entirely distinct matters. So I think that's a difficult balance to strike, Kristen.

Kristen Stewart

analyst
#48

All right. What about the scale of that particular client? Are we talking about a really big account? Could there be a danger that other buyers in that region might be affected somehow? It just seems a little strange that attention would center on only one buyer.

Liam Kelly

executive
#49

My view is that this reflects a highly particular emphasis from that office, though honestly, Kristen, I'd rather not get into specifics regarding any individual customer.

Jake Elguicze

executive
#50

Absolutely. Operator, thank you, and we appreciate all of you who came onto today's call. That brings an end to the Teleflex Incorporated Second Quarter 2020 Earnings Conference Call. Enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.